Previously considered a minor cannabinoid in terms of the overall cannabinoid profile, large amounts of CBDa have recently been shown to exist in certain ruderalis strains, as well as hybrids such as Cannatonic C-6 and ACDC. The levels of CBDa found in these strains and hybrids, in fact, are potentially higher than the levels of THCa. Decarboxylated when heated, CBDa becomes CBD in the same way that THCa becomes THC, and is not psychoactive. Research has shown that CBDa demonstrates anti-emetic (lessens vomit/nausea) and anti-proliferative (limits cancer cell growth) effects – in other words, an ideal choice to combat the effects of cancer. In addition, CBDa is also an anti-inflammatory (lessens inflammation) that possesses anti-bacterial properties.